Aligos Therapeutics (ALGS) EBITDA Margin (2021 - 2026)
Aligos Therapeutics' (ALGS) quarterly EBITDA Margin came in at 951.55% in Q1 2026, up 523591.0% YoY from N/an in Q1 2025, and up 92.63% on a QoQ basis from 12907.69% in Q4 2025.
Aligos Therapeutics (ALGS) EBITDA Margin (2021 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 6 years of EBITDA Margin data on file, last reported at 951.55% in Q1 2026.
- Quarterly EBITDA Margin rose 523591.0% year-over-year to 951.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2413.5% (down 17864003.0% YoY) and the FY2025 annual result came in at 4024.93%, up 2266788.0% from the prior year.
- EBITDA Margin rose to 951.55% in Q1 2026, from 12907.69% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 2284.45% in Q4 2023 to a low of 17084.29% in Q1 2023.
- A 5-year average of 3165.9% and a median of 1610.48% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin tumbled 1570128 bps — and 2024, when it soared 1390763 bps.
- Tracing ALGS's EBITDA Margin over 5 years: stood at 163.1% in 2022, then surged by 1501 bps to 2284.45% in 2023, then tumbled by 66 bps to 769.86% in 2024, then slumped by 1777 bps to 12907.69% in 2025, then soared by 93 bps to 951.55% in 2026.
- The last three EBITDA Margin figures came in at 951.55% (Q1 2026), 12907.69% (Q4 2025), and 1924.04% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 19.75% |
| 10 | Aligos Therapeutics | 70.20 Mn | 39.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -951.55% |
| Dec 31, 2025 | -12,907.69% |
| Jun 30, 2025 | -1,924.04% |
| Mar 31, 2025 | -6,187.46% |
| Dec 31, 2024 | 769.86% |
| Sep 30, 2024 | -1,610.48% |
| Jun 30, 2024 | -2,489.54% |
| Mar 31, 2024 | -3,176.66% |
| Dec 31, 2023 | 2,284.45% |
| Sep 30, 2023 | -1,757.70% |
| Jun 30, 2023 | -445.76% |
| Mar 31, 2023 | -17,084.29% |
| Dec 31, 2022 | -163.10% |
| Sep 30, 2022 | -461.47% |
| Mar 31, 2022 | -1,383.00% |
| Dec 31, 2021 | -10,340.05% |
| Sep 30, 2021 | -2,151.46% |
| Jun 30, 2021 | -1,913.59% |
| Mar 31, 2021 | -3,048.35% |